Evidence map›Paper›PMID 42082482›Full record

ArticleNature communications2026

Characterization of KRAS

Shengbin Peng, Youyan Zhang, Xi Lin, Chong Si, Robert Daniel Van Horn, Jack A Dempsey, Eva Goetz, Robert J Evans, Andrew Farber, Matthew J Vandekopple and 42 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Precision Targeting ofInternational journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors.

Shengbin Peng *Eli Lilly and Company, Indianapolis, IN, USA.
Youyan Zhang *Eli Lilly and Company, Indianapolis, IN, USA.
Xi LinEli Lilly and Company, Indianapolis, IN, USA.
Chong SiEli Lilly and Company, Indianapolis, IN, USA.
Robert Daniel Van HornEli Lilly and Company, Indianapolis, IN, USA.
Jack A DempseyEli Lilly and Company, Indianapolis, IN, USA.
Eva GoetzEli Lilly and Company, Indianapolis, IN, USA.
Robert J EvansEli Lilly and Company, Indianapolis, IN, USA.
Andrew FarberEli Lilly and Company, Indianapolis, IN, USA.
Matthew J VandekoppleEli Lilly and Company, Indianapolis, IN, USA.
Wenyu MingEli Lilly and Company, Indianapolis, IN, USA.
Hong GaoEli Lilly and Company, Indianapolis, IN, USA.
Chungping YuEli Lilly and Company, Indianapolis, IN, USA.
Wei Guo XuEli Lilly and Company, Indianapolis, IN, USA.
Nicholas E BrownEli Lilly and Company, Indianapolis, IN, USA.
Michele S DowlessEli Lilly and Company, Indianapolis, IN, USA.
Nicholas PulliamEli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0001-6090-9062
David A BardaEli Lilly and Company, Indianapolis, IN, USA.
Deqi GuoEli Lilly and Company, Indianapolis, IN, USA.
Serge L BouletEli Lilly and Company, Indianapolis, IN, USA.
Lysian HuberEli Lilly and Company, Indianapolis, IN, USA.
Andrew CapenEli Lilly and Company, Indianapolis, IN, USA.
Bonita JonesEli Lilly and Company, Indianapolis, IN, USA.
Sarah BognerEli Lilly and Company, Indianapolis, IN, USA.
Mark A CastanaresEli Lilly and Company, Indianapolis, IN, USA.
Jennifer Rachelle StephensEli Lilly and Company, Indianapolis, IN, USA.
Megan A JohnsonEli Lilly and Company, Indianapolis, IN, USA.
Carmen L CurtisEli Lilly and Company, Indianapolis, IN, USA.
John M StrelowEli Lilly and Company, Indianapolis, IN, USA.
Junpeng XiaoEli Lilly and Company, Indianapolis, IN, USA.
Josh BallardEli Lilly and Company, Indianapolis, IN, USA.
Wayne P BocchinfusoEli Lilly and Company, Indianapolis, IN, USA.
Michael J ChalmersEli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-2139-6089
Jing WangEli Lilly and Company, Indianapolis, IN, USA.
Jorg HendleEli Lilly and Company, Indianapolis, IN, USA.
Melbert D SaflorEli Lilly and Company, Indianapolis, IN, USA.
Danalyn Manglicmot LagutanEli Lilly and Company, Indianapolis, IN, USA.
Tarun GheyiEli Lilly and Company, Indianapolis, IN, USA.
Anita SarkarEli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0001-5602-8406
Margaret KearinsEli Lilly and Company, Indianapolis, IN, USA.
Frances TungEli Lilly and Company, Indianapolis, IN, USA.
Joseph HoEli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-9636-5527
Logan RodgersEli Lilly and Company, Indianapolis, IN, USA.
Jordi BenachEli Lilly and Company, Indianapolis, IN, USA.
Anton Joseph FrommeltEli Lilly and Company, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-0552-5856
Lian ZhouEli Lilly and Company, Indianapolis, IN, USA.
Bradley L AckermannEli Lilly and Company, Indianapolis, IN, USA.
Denis McCannEli Lilly and Company, Indianapolis, IN, USA.
Anke KlippelEli Lilly and Company, Indianapolis, IN, USA.
Sean G BuchananEli Lilly and Company, Indianapolis, IN, USA.
James R HenryEli Lilly and Company, Indianapolis, IN, USA.
Xueqian GongEli Lilly and Company, Indianapolis, IN, USA. gong_xueqian@lilly.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of first-generation covalent KRAS

Indexed as

Antineoplastic AgentsProto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorHumansImmune Checkpoint InhibitorsMiceMutationXenograft Model Antitumor AssaysAntineoplastic AgentsImmune Checkpoint InhibitorsKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID42082482
PMCPMC13346474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.